Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 2—February 2021
Dispatch

Prevalence of SARS-CoV-2–Specific Antibodies, Japan, June 2020

Takashi YoshiyamaComments to Author , Yasuki Saito, Kunitsugu Masuda, Yoshiko Nakanishi, Yasutoshi Kido, Kazuhiro Uchimura, Satoshi Mitarai, Tadaki Suzuki, Yu Nakagama, Hiroshi Kubota, Maki Satomi, Sana Uchikoba, Makoto Ohnishi, Takaji Wakita, Seiya Kato, and Katsunobu Kato
Author affiliations: Research Institute of Tuberculosis, Kiyose, Japan (T. Yoshiyama, K. Uchimura, S. Miatai, S. Kato); Fukujuji Kenshin Center of Miyagi Anti-Tuberculosis Association, Sendai, Japan (Y. Saito); Osaka Anti-Tuberculosis Association, Osaka, Japan (K. Masuda); Center for Comprehensive Health Check and Promotion of Japan Anti-Tuberculosis Association, Tokyo, Japan (Y. Nakanishi); Osaka City University, Osaka (Y. Kido, Y. Nakagama); National Institute of Infectious Diseases, Tokyo (T. Suzuki, M. Ohnishi, T. Wakita); Osaka City University Hospital, Osaka (H. Kubota); Ministry of Health, Labor and Welfare, Tokyo (M. Satomi, S. Uchikoba); Government of Japan, Tokyo (K. Kato)

Main Article

Table

Serologic results of 2 antibody tests for severe acute respiratory syndrome coronavirus 2, Japan, June 2020*

Characteristic
 Both +
 Roche –, Abbott +
 Roche +, Abbott –
 Both –
 Subtotal
 % Patients positive 
by both tests (95% CI)
Total
 8
 15
 15
 7,912
 7,950
 0.10 (0.04–0.20)
Area
Tokyo 2 2 4 1,963 1,971 0.10 (0.01–0.37)
Osaka 5 11 5 2,949 2,970 0.17 (0.05–0.39)
Miyagi
 1
 2
 6
 3,000
 3,009
 0.03 (0.00–0.19)
Sex
M 3 7 5 3,643 3,658 0.08 (0.02–0.24)
F
 5
 8
 10
 4,269
 4,292
 0.12 (0.04–0.27)
Age, y
20–29 3 0 0 875 878 0.34 (0.07–1.00)
30–39 3 2 1 1,210 1,216 0.25 (0.05–0.72)
40–49 0 3 7 1,589 1,599 0 (0.00–0.23)
50–59 0 2 4 1,457 1,463 0 (0.00–0.25)
60–69 1 4 0 1,315 1,320 0.08 (0.00–0.42)
70–79 1 4 1 1,128 1,134 0.09 (0.00–0.49)
>80
 0
 0
 2
 338
 340
 0 (0.00–1.08)
Job setting
Working as before 4 4 3 3,091 3,102 0.13 (0.04–0.33)
Working at home 0 3 2 432 437 0 (0.00–0.84)
Working as before and at home 1 1 5 1,974 1,981 0.05 (0.00–0.28)
Not working 3 7 5 2,410 2,425 0.12 (0.03–0.36)
No information
 0
 0
 0
 5
 5
 0 (0.00–52.20)
Time spent outside the home, h
0 1 4 1 1,153 1,159 0.09 (0.00–0.48)
<2 1 5 6 2,871 2,883 0.03 (0.00–0.19)
2–4 3 5 5 1,182 1,195 0.25 (0.05–0.73)
>4 3 1 3 2,704 2,711 0.11 (0.02–0.32)
No information
 0
 0
 0
 2
 2
 0 (0.00–84.20)
Fever at time of study
Yes 0 0 0 16 16 0 (0.00–20.60)
No 8 15 15 7,886 7,924 0.10 (0.04–0.20)
No information
 0
 0
 0
 10
 10
 0 (0.00–30.90)
History of fever lasting >4 days in past 4 months
Yes 4 1 1 155 161 2.48 (0.68–6.24)
No 4 14 14 7,756 7,788 0.05 (0.01–0.13)
No information
 0
 0
 0
 1
 1
 0 (0.00–97.50)
Previous PCR result
Positive 1 0 0 0 1 100.00 (2.50–100.00)
Negative 0 0 0 33 33 0 (0.00–10.60)
Not applicable
 7 15 15 7,879 7,916 0.09 (0.04–0.18)

*Roche, Elecsys Anti SARS-CoV-2 (F. Hoffmann-La Roche Ltd, https://www.roche.com); Abbott, ARCHITECT SARS-CoV-2 IgG assay (Abbott, https://www.abbott.com); +, positive; –, negative.

Main Article

Page created: November 05, 2020
Page updated: January 24, 2021
Page reviewed: January 24, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external